Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2005;96:100-109
Published online before print December 2, 2004, doi: 10.1161/01.RES.0000152262.22968.72
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
96/1/100    most recent
01.RES.0000152262.22968.72v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takimoto, E.
Right arrow Articles by Kass, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takimoto, E.
Right arrow Articles by Kass, D. A.
Related Collections
Right arrow Contractile function
Right arrow Cardiovascular Pharmacology
Right arrow Cell biology/structural biology
(Circulation Research. 2005;96:100.)
© 2005 American Heart Association, Inc.


Cellular Biology

cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism

Eiki Takimoto*, Hunter C. Champion*, Diego Belardi*, Javid Moslehi, Marco Mongillo, Evanthia Mergia, David C. Montrose, Takayoshi Isoda, Kate Aufiero, Manuela Zaccolo, Wolfgang R. Dostmann, Carolyn J. Smith, David A. Kass

From the Division of Cardiology (E.T., H.C.C., D.B., J.M., T.I., D.A.K.), Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Md; Dulbecco Telethon Institute at the Venetian Institute of Molecular Medicine (M.M., M.Z.), Padova, Italy; Department of Pharmacology and Toxicology (E.M.), Ruhr-Universität Bochum, Medizinische Fakultät, Bochum, Germany; Department of Pharmacology (D.C.M., K.A., C.J.S.), New York Medical College, Valhalla; and Department of Pharmacology (W.R.D.), University of Vermont, Burlington.

Correspondence to David A. Kass, Ross Research Bldg 835, Johns Hopkins University Hospital, 720 Rutland Ave, Baltimore, MD 21205. E-mail dkass{at}jhmi.edu

ß-Adrenergic agonists stimulate cardiac contractility and simultaneously blunt this response by coactivating NO synthase (NOS3) to enhance cGMP synthesis and activate protein kinase G (PKG-1). cGMP is also catabolically regulated by phosphodiesterase 5A (PDE5A). PDE5A inhibition by sildenafil (Viagra) increases cGMP and is used widely to treat erectile dysfunction; however, its role in the heart and its interaction with ß-adrenergic and NOS3/cGMP stimulation is largely unknown. In nontransgenic (control) murine in vivo hearts and isolated myocytes, PDE5A inhibition (sildenafil) minimally altered rest function. However, when the hearts or isolated myocytes were stimulated with isoproterenol, PDE5A inhibition was associated with a suppression of contractility that was coupled to elevated cGMP and increased PKG-1 activity. In contrast, NOS3-null hearts or controls with NOS inhibited by NG-nitro-L-arginine methyl ester, or soluble guanylate cyclase (sGC) inhibited by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline-1-one, showed no effect of PDE5A inhibition on ß-stimulated contractility or PKG-1 activation. This lack of response was not attributable to altered PDE5A gene or protein expression or in vitro PDE5A activity, but rather to an absence of sGC-generated cGMP specifically targeted to PDE5A catabolism and to a loss of PDE5A localization to z-bands. Re-expression of active NOS3 in NOS3-null hearts by adenoviral gene transfer restored PDE5A z-band localization and the antiadrenergic efficacy of PDE5A inhibition. These data support a novel regulatory role of PDE5A in hearts under adrenergic stimulation and highlight specific coupling of PDE5A catabolic regulation with NOS3-derived cGMP attributable to protein subcellular localization and targeted synthetic/catabolic coupling.


Key Words: PDE5 • phosphodiesterase • sildenafil • nitric oxide synthase • contractility • z-band




This article has been cited by other articles:


Home page
CirculationHome page
H. C. Champion, E. D. Michelakis, and P. M. Hassoun
Comprehensive Invasive and Noninvasive Approach to the Right Ventricle-Pulmonary Circulation Unit: State of the Art and Clinical and Research Implications
Circulation, September 15, 2009; 120(11): 992 - 1007.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. S. Buys, A. Cauwels, M. J. Raher, J. J. Passeri, I. Hobai, S. M. Cawley, K. M. Rauwerdink, H. Thibault, P. Y. Sips, R. Thoonen, et al.
sGC{alpha}1{beta}1 attenuates cardiac dysfunction and mortality in murine inflammatory shock models
Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H654 - H663.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Reffelmann and R. A. Kloner
Phosphodiesterase 5 inhibitors: are they cardioprotective?
Cardiovasc Res, July 15, 2009; 83(2): 204 - 212.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Hsu, T. Nagayama, N. Koitabashi, M. Zhang, L. Zhou, D. Bedja, K. L. Gabrielson, J. D. Molkentin, D. A. Kass, and E. Takimoto
Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway
Cardiovasc Res, February 1, 2009; 81(2): 301 - 309.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Pokreisz, S. Vandenwijngaert, V. Bito, A. Van den Bergh, I. Lenaerts, C. Busch, G. Marsboom, O. Gheysens, P. Vermeersch, L. Biesmans, et al.
Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice
Circulation, January 27, 2009; 119(3): 408 - 416.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Nagayama, S. Hsu, M. Zhang, N. Koitabashi, D. Bedja, K. L. Gabrielson, E. Takimoto, and D. A. Kass
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.
J. Am. Coll. Cardiol., January 13, 2009; 53(2): 207 - 215.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
M. Guazzi
Clinical Use of Phosphodiesterase-5 Inhibitors in Chronic Heart Failure
Circ Heart Fail, November 1, 2008; 1(4): 272 - 280.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Das, L. Xi, and R. C. Kukreja
Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3{beta}
J. Biol. Chem., October 24, 2008; 283(43): 29572 - 29585.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Nagayama, M. Zhang, S. Hsu, E. Takimoto, and D. A. Kass
Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 380 - 387.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. G. Tankersley, H. C. Champion, E. Takimoto, K. Gabrielson, D. Bedja, V. Misra, H. El-Haddad, R. Rabold, and W. Mitzner
Exposure to inhaled particulate matter impairs cardiac function in senescent mice
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R252 - R263.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. W. M. Nausch, J. Ledoux, A. D. Bonev, M. T. Nelson, and W. R. Dostmann
Differential patterning of cGMP in vascular smooth muscle cells revealed by single GFP-linked biosensors
PNAS, January 8, 2008; 105(1): 365 - 370.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. A. Kass, H. C. Champion, and J. A. Beavo
Phosphodiesterase Type 5: Expanding Roles in Cardiovascular Regulation
Circ. Res., November 26, 2007; 101(11): 1084 - 1095.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. A. Kass
Hypertrophied Right Hearts Get Two for the Price of One: Can Inhibiting Phosphodiesterase Type 5 Also Inhibit Phosphodiesterase Type 3?
Circulation, July 17, 2007; 116(3): 233 - 235.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. A. Kass, E. Takimoto, T. Nagayama, and H. C. Champion
Phosphodiesterase regulation of nitric oxide signaling
Cardiovasc Res, July 15, 2007; 75(2): 303 - 314.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
N. G. Perez, M. R. Piaggio, I. L. Ennis, C. D. Garciarena, C. Morales, E. M. Escudero, O. H. Cingolani, G. Chiappe de Cingolani, X.-P. Yang, and H. E. Cingolani
Phosphodiesterase 5A Inhibition Induces Na+/H+ Exchanger Blockade and Protection Against Myocardial Infarction
Hypertension, May 1, 2007; 49(5): 1095 - 1103.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. Takimoto, D. Belardi, C. G. Tocchetti, S. Vahebi, G. Cormaci, E. A. Ketner, A. L. Moens, H. C. Champion, and D. A. Kass
Compartmentalization of Cardiac {beta}-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5
Circulation, April 24, 2007; 115(16): 2159 - 2167.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. L. Hsu, H. C. Champion, S. A. Campbell-Lee, T. J. Bivalacqua, E. A. Manci, B. A. Diwan, D. M. Schimel, A. E. Cochard, X. Wang, A. N. Schechter, et al.
Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability
Blood, April 1, 2007; 109(7): 3088 - 3098.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. W. Elrod, J. J. M. Greer, and D. J. Lefer
Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H342 - H347.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Y. Maslov, V. P. Chacko, M. Stuber, A. L. Moens, D. A. Kass, H. C. Champion, and R. G. Weiss
Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H387 - H391.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele
Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases
Circ. Res., October 13, 2006; 99(8): 816 - 828.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
P. Fesler, A. Pagnamenta, B. Rondelet, F. Kerbaul, and R. Naeije
Effects of sildenafil on hypoxic pulmonary vascular function in dogs
J Appl Physiol, October 1, 2006; 101(4): 1085 - 1090.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. R.V. Castro, I. Verde, D. M.F. Cooper, and R. Fischmeister
Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes
Circulation, May 9, 2006; 113(18): 2221 - 2228.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Mongillo, C. G. Tocchetti, A. Terrin, V. Lissandron, Y.-F. Cheung, W. R. Dostmann, T. Pozzan, D. A. Kass, N. Paolocci, M. D. Houslay, et al.
Compartmentalized Phosphodiesterase-2 Activity Blunts {beta}-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway
Circ. Res., February 3, 2006; 98(2): 226 - 234.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. A. Borlaug, V. Melenovsky, T. Marhin, P. Fitzgerald, and D. A. Kass
Sildenafil Inhibits {beta}-Adrenergic-Stimulated Cardiac Contractility in Humans
Circulation, October 25, 2005; 112(17): 2642 - 2649.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. A. Kass
Ventricular Arterial Stiffening: Integrating the Pathophysiology
Hypertension, July 1, 2005; 46(1): 185 - 193.
[Abstract] [Full Text] [PDF]